How do I choose between different small-molecule API CDMO providers for scale-up, analytics, and confidentiality?

Choosing a small-molecule API CDMO is usually less about finding the “best” vendor overall and more about finding the best fit for your molecule, stage, risk tolerance, and confidentiality needs. A good way to compare providers is to score them across three buckets: scale-up capability, analytical depth, and confidentiality/IP protection.

1) Start with your real need

Before comparing CDMOs, define:

• Current stage: route scouting, kilo lab, pilot, or commercial
• Molecule type: straightforward small molecule vs. highly potent, chiral, unstable, or moisture/oxygen-sensitive
• Target scale: grams, kilograms, tens/hundreds of kg, or commercial
• Regulatory stage: preclinical, clinical, or commercial
• Must-have analytics: method development, impurity ID, residual solvents, genotox impurities, solid-state work, stability
• Confidentiality concerns: novel route, proprietary intermediate, trade-secret process parameters, patent strategy timing

That helps you avoid overpaying for capabilities you don’t need or, worse, choosing a provider that can’t support later scale.

2) Evaluate scale-up capability

For scale-up, look beyond “they can make API” and ask how they transfer chemistry from lab to plant.

Key questions

• Have they scaled chemistries similar to yours?
• What reactor types and unit operations do they have?
  • low-temperature control
  • hydrogenation
  • cryogenic reactions
  • high-pressure chemistry
  • filtration/drying
  • crystallization and polymorph control
• Can they handle your hazard profile?
  • exothermic reactions
  • toxic reagents
  • moisture-sensitive steps
  • pyrophorics
• Do they have strong process safety:
  • calorimetry
  • reaction hazard assessment
  • impurity risk assessment
  • EHS documentation
• Can they support process optimization:
  • yield improvement
  • impurity purge
  • solvent and reagent reduction
  • cycle time reduction
• Do they have capacity flexibility:
  • dedicated equipment vs shared suites
  • ability to scale from g to kg to pilot
  • backup manufacturing options if a line is down

Signs of a strong scale-up CDMO

• Clear tech transfer process
• Process chemistry and engineering teams work together
• They ask smart questions about impurity formation and isolation
• They can show examples of de-risking a route before scale-up
• They have experience with crystallization, isolation, and drying—not just synthesis

3) Evaluate analytical capabilities

Analytics can make or break a project, especially when you move from discovery to development.

What to look for

• Method development and validation
  • HPLC/UPLC
  • GC
  • LC-MS / HRMS
  • NMR
  • chiral analysis
  • KF water
  • ICP-MS for metals
• Impurity profiling
  • process impurities
  • degradants
  • residual reagents/catalysts
  • genotoxic impurities if relevant
• Solid-state characterization
  • polymorph screening
  • XRPD
  • DSC/TGA
  • particle size analysis
• Stability support
  • forced degradation
  • ICH stability studies
  • photostability if needed
• Regulatory readiness
  • GMP documentation
  • method transfer and validation packages
  • data integrity practices
  • audit trails and controlled systems

Questions to ask

• Do you have in-house analytical development, or do you outsource key testing?
• Can you identify unknown impurities, not just report them?
• Can you support method transfer into GMP?
• How quickly can you turn around analytical results during process development?
• Do you have experience with low-level impurity detection and trace analytics?

Warning signs

• They can run routine assays but struggle to identify unknowns
• They rely heavily on external labs for critical testing
• They do not clearly separate development analytics from release testing
• Their documentation seems thin for regulated work

4) Evaluate confidentiality and IP protection

For many clients, this is the most sensitive issue. A good CDMO should be able to protect both your trade secrets and your patent position.

What to assess

• Legal protections
  • NDA quality and scope
  • IP ownership terms
  • invention assignment clauses
  • background vs foreground IP definitions
• Operational controls
  • need-to-know access
  • restricted document access
  • data segregation
  • controlled sample handling
  • visitor and subcontractor controls
• Technical controls
  • secure electronic systems
  • audit trails
  • cybersecurity practices
  • encrypted file transfer
• Organizational culture
  • do they treat confidentiality seriously in practice?
  • do project teams communicate carefully and document access?
• Subcontracting policy
  • do they outsource analysis or steps without your explicit approval?
  • do they disclose supplier names or intermediates?

Good questions

• Who will have access to my project information?
• Will you use any subcontractors, and if so, under what controls?
• How do you manage document retention and electronic access?
• Can you support blind or compartmentalized development if needed?
• How do you prevent cross-project knowledge sharing?

Red flags

• Loose talk about other clients’ projects
• Vague answers on subcontracting
• Weak NDA terms or unwillingness to negotiate IP clauses
• No clear data security or access control policy

5) Compare providers using a structured scorecard

A simple weighted matrix can help.

Example criteria:

• Scale-up chemistry fit — 30%
• Analytical capability — 25%
• Confidentiality/IP protection — 25%
• Quality/regulatory systems — 10%
• Communication/project management — 10%

Score each provider from 1–5 and compare total weighted scores. The right weights depend on your priorities:

• Early discovery: chemistry flexibility and speed may matter most
• Preclinical/clinical: analytics and quality systems matter more
• Proprietary route: confidentiality may be the top priority

6) Run a practical due diligence process

Shortlist 3–5 providers and do:

1. Capability questionnaire
2. Technical teleconference with chemistry + analytical leads
3. Quality and confidentiality review
4. Reference checks
5. Audit or site visit if the project is important or regulated
6. Pilot project or feasibility batch before full scale-up

A small paid feasibility study can reveal a lot:

• how they communicate
• how they handle uncertainty
• whether their analytical tools are adequate
• how disciplined their project management is

7) Common trade-offs to expect

• Big, established CDMO: better quality systems and scale, but may be slower and less flexible
• Smaller specialist CDMO: more responsive and often stronger chemistry collaboration, but may have limited capacity or analytics
• Low-cost provider: attractive pricing, but verify quality, transparency, and IP protections carefully

8) Practical decision rule

If your project is:

• Chemically complex or hazardous: prioritize scale-up experience and process safety
• Analytically challenging: prioritize in-house analytical depth and impurity expertise
• IP-sensitive: prioritize confidentiality controls, subcontracting discipline, and contractual protections
• GMP-bound: prioritize quality systems and regulatory track record

9) What to ask in the first round

Use these as a starting checklist:

• What similar APIs have you scaled?
• What is your maximum and typical batch size?
• Which analytical methods are in-house?
• How do you handle unknown impurities?
• What are your data security and confidentiality controls?
• Do you subcontract any work?
• What is your tech transfer process?
• What is your typical timeline from feasibility to GMP batch?
• Can you provide references from similar programs?

If you want, I can also give you:

1. a CDMO vendor scorecard template,
2. a due diligence questionnaire, or
3. a side-by-side comparison matrix you can use with shortlisted providers.